|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
The detrimental actions of the AT1 receptor (AT1R) in hypertension and vascular injury, myocardial infarction and brain ischemia are well established.
|
24414230 |
2014 |
|
Hypertensive disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Previous studies have shown that angiotensin II AT1 receptor gene (AT1R) polymorphisms are associated with the risk for hypertension.
|
25990648 |
2015 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Purinergic P2Y6 receptors heterodimerize with angiotensin AT1 receptors to promote angiotensin II-induced hypertension.
|
26787451 |
2016 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
The AT1 receptor promotes various intracellular signaling pathways resulting in hypertension, endothelial dysfunction, vascular remodeling and end organ damage.
|
28527699 |
2017 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Losartan is a selective antagonist of AngⅠ type (AT1) receptor of Angiotensin Ⅱ (Ang Ⅱ), which is widely used as a clinical medicine for the hypertension.
|
28483563 |
2017 |
|
Hypertensive disease
|
0.100 |
AlteredExpression
|
group |
BEFREE |
G4+/- offspring on a HFD displayed early hypertension associated with increased renal gene expression of renin and the AT1- receptors compared to G4+/- on a C diet.
|
28750406 |
2017 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
We hypothesized that enhanced constrictive responsiveness of renal afferent arterioles (Af-Art) to angiotensin II (ANG II) mediated by ANG II type 1 (AT1) receptors contributes to the development of hypertension in diabetes.
|
28842434 |
2017 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
In the present work, we explored the changes in the expression of angiotensin II receptor, type 1 (AT<sub>1</sub> receptor) in limbic structures, as well as the effect of the AT1 receptor antagonist losartan in a model of comorbid hypertension and epilepsy.
|
29223539 |
2018 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, our data show that spinal ionotropic glutamatergic and AT1 receptors contribute to increased rSNA in the 2K1C model, leading to the maintenance of hypertension; however, the participation of spinal AT1 receptors seems to be especially important in the establishment of sympathoexcitation in this model.
|
29935157 |
2018 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Central blockade of the AT1 receptor attenuates pressor effects via reduction of glutamate release and downregulation of NMDA/AMPA receptors in the rostral ventrolateral medulla of rats with stress-induced hypertension.
|
30842613 |
2019 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Findings support that FPH is associated with a vascular hyper-sympathetic activation, involving a tonic facilitation of prejunctional AT1 receptors by endogenous Ang II, which can justify, at least in part, the development of hypertension.
|
30326265 |
2019 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Compound 21 (C21), selective AT2 receptor agonist, has cardioprotective effects in experimental models of hypertension and myocardial infarction.
|
30187136 |
2019 |
|
Hypertensive disease
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Although exogenous angiotensin II (AngII) can increase NMDAR activity in the PVN, whether endogenous AT1 receptor-protein kinase C (PKC) activity mediates the augmented NMDAR activity of PVN presympathetic neurons in hypertension is unclear.
|
31241170 |
2019 |
|
Hypertensive disease
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our data indicate an essential and systemic role for TG2 in bridging inflammation to hypertension via its posttranslational modifications stabilizing AT1 receptor and sensitizing Ang II.
|
30715101 |
2019 |